Why GLP-1 Medications Work Better With Hormone Support

The GLP-1 and Hormone Synergy: What the Science Shows

GLP-1 (glucagon-like peptide-1) receptor agonists work by mimicking a naturally occurring gut hormone that signals satiety, slows gastric emptying, and reduces appetite. What’s often overlooked is that these receptors don’t exist in isolation — they interact with the broader hormonal environment of the body, including estrogen and testosterone.

Emerging research published in journals including Obesity and The Journal of Clinical Endocrinology & Metabolism suggests that estrogen may upregulate GLP-1 receptor expression in the hypothalamus — the brain’s central hub for appetite and metabolic regulation. When estrogen levels fall, as they do during perimenopause, some of this receptor activity may diminish, potentially reducing the effectiveness of GLP-1 signaling whether endogenous or exogenous.

This is not a simple on/off switch. Hormonal influence on GLP-1 sensitivity exists on a spectrum, and individual responses vary considerably. But the underlying biology provides a compelling rationale for why women in hormonal transition sometimes find that GLP-1 medications, while helpful, may not deliver the full response they expected — and why hormone support may change the picture.

Estrogen’s Role in GLP-1 Receptor Sensitivity

Estrogen receptors are distributed throughout the body — including in the gut, pancreas, brain, and adipose tissue. In the gut, estrogen appears to influence the release of endogenous GLP-1 from L-cells in the intestinal lining. In the brain, estrogen interacts with hypothalamic circuits that govern energy intake and expenditure.

Animal studies have demonstrated that estrogen-deficient female rodents show reduced GLP-1-mediated appetite suppression compared to estrogen-replete controls. While human data is still accumulating, observational evidence suggests that postmenopausal women — who have lower estrogen levels — may experience a blunted response to GLP-1 therapies compared to premenopausal women.

Progesterone’s role is less clearly defined, though some research suggests it may have modest opposing effects on insulin sensitivity during the luteal phase of the menstrual cycle. During perimenopause, the erratic fluctuation of both estrogen and progesterone creates a highly variable hormonal environment — one that may unpredictably affect GLP-1 receptor activity from month to month.

For clinicians managing perimenopausal women on semaglutide or tirzepatide, this complexity underscores the importance of hormonal evaluation as part of the treatment picture. Stabilizing estrogen — where clinically appropriate — may help create a more consistent and favorable environment for GLP-1 therapy to work effectively.

The Menopause Society supports individualized hormone therapy evaluation for women in the perimenopausal transition, noting that the risks and benefits must be weighed carefully for each patient.

Muscle Preservation on Tirzepatide and Semaglutide: The Sarcopenia Risk in Perimenopause

One of the most significant — and underappreciated — risks of GLP-1 therapy in perimenopausal women is muscle loss. When patients lose weight rapidly, a portion of that weight loss typically comes from lean mass, not just fat. Studies suggest that without intervention, roughly 25–39% of weight lost on GLP-1 medications may come from muscle tissue.

For perimenopausal women, this risk is amplified. Natural sarcopenia (age-related muscle loss) accelerates around the time of menopause, driven in part by declining estrogen and testosterone. Women can lose 1–2% of muscle mass per year beginning in their 40s. Layering GLP-1-induced weight loss on top of this existing trajectory without a plan to preserve muscle creates a real risk of sarcopenic obesity — a condition where body fat percentage remains elevated even as scale weight drops, and metabolic function may actually worsen.

The Role of Testosterone in Muscle Preservation

Testosterone is often thought of as a male hormone, but women produce it too — and it plays a direct role in muscle protein synthesis. Testosterone binds to androgen receptors in muscle tissue, stimulating the production of contractile proteins that maintain strength and mass.

As women enter perimenopause, testosterone levels may decline alongside estrogen — though the trajectory varies considerably. Women with lower testosterone may find that the muscle-preserving adaptations to resistance training are less robust, and that muscle loss during caloric restriction is more pronounced.

Some patients report that low-dose testosterone therapy (when clinically indicated) may support muscle preservation during GLP-1 treatment, though individual responses vary significantly. Combining testosterone support with an adequate protein intake (typically 1.2–1.6g per kilogram of body weight daily) and structured resistance training is generally considered the strongest approach to maintaining lean mass during GLP-1 therapy.

Protein, Exercise, and the Preservation Protocol

Regardless of hormone status, the foundation of muscle preservation during GLP-1 therapy includes:

• High-protein dietary intake to support muscle protein synthesis
• Progressive resistance training at least 2–3 times per week
• Adequate caloric intake — severe restriction accelerates muscle loss
• Regular body composition monitoring (DEXA or bioelectrical impedance)
• Hormone evaluation and optimization where clinically appropriate

Who Is Most Affected: Perimenopausal Women 40–55

Perimenopause — the transitional phase preceding menopause, typically spanning 4–10 years — is a period of profound hormonal volatility. Estrogen levels fluctuate erratically before ultimately declining. Progesterone production falls as ovulation becomes less reliable. Testosterone levels drift downward. The result is a metabolic environment that is particularly challenging for weight management.

Women in this group often report that strategies that worked reliably in their 30s — the same diet, the same exercise routine — no longer produce the same results. This is not a failure of willpower or effort. It reflects real physiological change: shifting fat distribution toward the abdomen, increased insulin resistance, disrupted sleep (which elevates cortisol and reduces growth hormone), and reduced basal metabolic rate.

GLP-1 medications address several of these drivers — appetite dysregulation, insulin resistance, and caloric overconsumption. But they work within a hormonal context. For perimenopausal women whose hormonal environment is in flux, addressing that context concurrently may be essential to achieving the full potential of GLP-1 therapy.

Women who are most likely to benefit from combined GLP-1 and hormone support typically present with:

• BMI ≥27 with at least one weight-related comorbidity, or BMI ≥30
• Perimenopausal symptoms: irregular cycles, hot flashes, night sweats, mood changes, sleep disruption
• Documented suboptimal estrogen and/or testosterone levels on lab evaluation
• Prior difficulty with weight loss despite appropriate caloric restriction and exercise
• Concerns about muscle loss or declining physical function

Evaluation and Labs: What to Look For

A thorough initial evaluation is essential for women considering combined GLP-1 and hormone therapy. At LiteWell, this typically includes a comprehensive hormone panel alongside metabolic and body composition assessment.

Hormone labs to consider:

• Estradiol (E2) — primary form of estrogen during reproductive years
• Progesterone — particularly useful when timed to the luteal phase
• Total and free testosterone
• DHEA-S — adrenal androgen precursor
• FSH and LH — elevated levels help confirm perimenopausal/menopausal transition
• Thyroid panel (TSH, free T3, free T4) — thyroid dysfunction is common in this age group and can mimic hormonal symptoms
• Fasting insulin and HbA1c — to assess insulin resistance and glycemic status

Body composition and metabolic markers:

• DEXA scan or validated body composition assessment
• Fasting lipid panel
• Comprehensive metabolic panel
• Blood pressure and resting heart rate

Lab interpretation in perimenopause requires clinical nuance. “Normal range” values for estrogen, for example, span a wide range across the reproductive lifespan — and what’s normal for a 25-year-old may be suboptimal for symptom control in a 48-year-old. Physician interpretation in context is essential.

The Combined Treatment Approach

When clinical evaluation supports both GLP-1 therapy and hormone support, the two are typically integrated thoughtfully rather than started simultaneously at maximum doses. A sequenced or concurrent low-dose initiation approach allows physicians to assess tolerability, monitor labs, and adjust based on individual response.

GLP-1 medication initiation: Semaglutide and tirzepatide are both initiated at low doses and titrated gradually over weeks to months. This approach minimizes gastrointestinal side effects and allows the body to adapt. Individual responses vary — some patients reach target doses quickly; others require longer titration periods.

Compounded semaglutide and tirzepatide are not FDA-approved drugs. They are prepared by licensed compounding pharmacies and prescribed by physicians when clinically appropriate. This content is for educational purposes only.

Hormone therapy considerations: Options for hormone support in perimenopausal women include bioidentical estrogen (typically transdermal patches, gels, or creams to avoid first-pass hepatic metabolism), progesterone (micronized oral progesterone for women with an intact uterus), and testosterone (compounded topical preparations at physiologic doses for women). The appropriate form, dose, and delivery route depends on the individual patient’s hormone levels, symptoms, medical history, and preferences.

Nutrition and exercise: Adequate protein intake and structured resistance training are non-negotiable components of any GLP-1 protocol for perimenopausal women. These are not optional add-ons — they are foundational to the outcome.

Monitoring: Regular follow-up appointments, repeat labs, and body composition tracking allow the clinical team to adjust protocols as needed. GLP-1 therapy and hormone support are not set-it-and-forget-it interventions — they require ongoing evaluation and refinement.

Dr. Kingsley’s Clinical Perspective

In our practice, one of the common patterns I see is a perimenopausal woman who has been told that GLP-1 medications are working “as expected” — but who isn’t losing the weight she hoped for, is losing muscle she can’t afford to lose, or is feeling worse overall despite losing pounds on the scale. When we look closer, we almost always find a hormonal picture that’s contributing to the disconnect.

Estrogen and testosterone aren’t just about reproduction — they are metabolic hormones. They govern how the body distributes fat, how efficiently it builds and retains muscle, how well it responds to appetite-regulating signals, and how effectively it converts food into energy versus storage. When those hormones are declining or fluctuating erratically, as they do in perimenopause, GLP-1 medications may be working against a significant headwind.

What I’ve observed in patients who receive appropriate hormone support alongside GLP-1 therapy is often a more consistent response, better preservation of lean mass, improved energy and mood, and — critically — a more sustainable trajectory. The goal is never just scale weight. It’s body composition, metabolic health, and quality of life. Hormone optimization is a meaningful part of achieving that for women in this life stage. Individual results vary, and not every patient is a candidate for hormone therapy — but for those who are, the difference can be significant.

— Kyle Kingsley, MD, Medical Director, LiteWell

Myths vs. Facts

Myth: GLP-1 medications work the same way regardless of your hormone levels.
Fact: Emerging evidence suggests estrogen may influence GLP-1 receptor sensitivity in the brain and gut. Hormonal status may affect how robustly a patient responds to GLP-1 therapy, though individual variation is significant.

Myth: Muscle loss on GLP-1 medications is inevitable and can’t be prevented.
Fact: While GLP-1 medications can contribute to lean mass reduction if caloric intake falls significantly, a structured approach combining adequate protein intake, resistance training, and — where appropriate — hormone optimization can substantially mitigate this risk.

Myth: Testosterone is not relevant for women’s weight management.
Fact: Testosterone plays a direct role in muscle protein synthesis in women. Low testosterone may impair the muscle-preserving response to resistance training and may contribute to more pronounced lean mass loss during weight loss interventions.

Myth: If the scale is moving, the treatment is working well.
Fact: Scale weight alone does not distinguish fat loss from muscle loss. Body composition monitoring is essential to ensure that weight loss outcomes translate to genuine improvements in metabolic health and physical function.

The LiteWell Approach

At LiteWell, we believe that effective weight management for perimenopausal women requires a framework that goes beyond prescribing a single medication and monitoring the scale. Our approach is integrative, data-driven, and built around the individual.

Every patient begins with a comprehensive evaluation that includes hormone labs, metabolic markers, and body composition assessment. We don’t assume that a woman in her mid-40s who is struggling to lose weight despite eating well and exercising consistently is simply not trying hard enough. We look for the physiological drivers — and hormonal imbalance is among the most common we find.

When GLP-1 therapy is appropriate, we initiate it with a structured protocol that includes nutritional guidance emphasizing adequate protein intake, a resistance training framework tailored to the individual’s fitness level and joint health, and a clear monitoring schedule. For women who also have evidence of hormonal deficiency, we discuss hormone therapy options in detail — including the evidence, the risks, the benefits, and the alternatives — so that each patient can make an informed decision about her own care.

We understand that perimenopausal weight management is not a six-week challenge — it’s a sustained clinical partnership. Our goal is to help our patients build a metabolic foundation that supports their health not just through perimenopause, but through the years that follow. That means optimizing all the relevant factors, not just one.

If you’re a woman in your 40s or 50s who has been frustrated by weight that isn’t responding the way it used to, we invite you to explore what a comprehensive, hormone-aware approach might look like for you. Schedule a free medical fit call to speak with a LiteWell physician about your options.

References

1. Mauvais-Jarvis F, et al. “Sex and Gender: Modifiers of Health, Disease, and Medicine.” The Lancet. 2020;396(10250):565–582.
2. Ding EL, et al. “Sex differences of endogenous sex hormones and risk of type 2 diabetes.” JAMA. 2006;295(11):1288–1299.
3. Lim SS, et al. “A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010.” The Lancet. 2012.
4. Menopause Society (formerly NAMS). “The 2023 Nonhormone Therapy Position Statement of The Menopause Society.” Available at: menopause.org.
5. Vilsbøll T, et al. “Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.” BMJ. 2012;344:d7771.
6. Colleluori G, Villareal DT. “Combining aerobic and resistance exercise to combat sarcopenic obesity in older adults.” Nutrients. 2021;13(8):2789.
7. Davis SR, et al. “Global Consensus Position Statement on the Use of Testosterone Therapy for Women.” J Clin Endocrinol Metab. 2019;104(10):4660–4666.